LANTUS® Plus Orals Provides Effective Glycemic Control
LANTUS® + orals effectively lowered A1C more than 1% in patients inadequately
controlled on oral agents alone5
Supervised titration resulted in substantial fasting plasma glucose (FPG) reductions6
Preliminary data from a 24-week, multicenter, randomized, parallel, open-label trial
of 756 overweight men and women compared the abilities and associated hypoglycemic
effects of LANTUS® long-acting (basal) insulin added to prestudy oral diabetes
medications (OADs) (n=367) vs NPH insulin (n=389) added to prestudy OADs in insulin-naïve
patients with inadequate glycemic control (A1C >7.5%) on 1 or 2 oral agents (sulfonylureas,
metformin, or thiazolidinediones) and treated to a target A1C ≤7.0%.
From data on file.6
- For the 24-hour glucose-lowering effect of LANTUS®, titrate the LANTUS®
dose to target FPG5
- Patients achieved an average A1C of 6.96% with LANTUS® + oral agents5
A 24-week, multicenter, randomized, parallel, open-label trial compared the effects
of LANTUS® (n=367) and NPH insulin (n=389) in insulin-naïve patients with inadequate
glycemic control on 1 or 2 oral agents (sulfonylureas, metformin, or thiazolidinediones).
From Riddle et al.5
- The majority of patients achieved A1C goals
- 1.7% mean A1C reduction at 24 weeks
Next: Switching from Premix to Lantus